Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

J. P. Clancy, Steven M. Rowe, Frank J. Accurso, Moira L. Aitken, Raouf S. Amin, Melissa A. Ashlock, Manfred Ballmann, Michael P. Boyle, Inez Bronsveld, Preston W. Campbell, Kris De Boeck, Scott H. Donaldson, Henry L. Dorkin, Jordan M. Dunitz, Peter R. Durie, Manu Jain, Anissa Leonard, Karen S. McCoy, Richard B. Moss, Joseph M. PilewskiDaniel B. Rosenbluth, Ronald C. Rubenstein, Michael S. Schechter, Martyn Botfield, Claudia L. Ordoñez, George T. Spencer-Green, Laurent Vernillet, Steve Wisseh, Karl Yen, Michael W. Konstan

Research output: Contribution to journalArticlepeer-review

445 Scopus citations


Background: VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro. Methods: A randomised, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacodynamics of VX-809 in adult patients with cystic fibrosis (n=89) who were homozygous for the F508del-CFTR mutation. Subjects were randomised to one of four VX-809 28 day dose groups (25, 50, 100 and 200 mg) or matching placebo. Results: The type and incidence of adverse events were similar among VX-809- and placebo-treated subjects. Respiratory events were the most commonly reported and led to discontinuation by one subject in each active treatment arm. Pharmacokinetic data supported a once-daily oral dosing regimen. Pharmacodynamic data suggested that VX-809 improved CFTR function in at least one organ (sweat gland). VX-809 reduced elevated sweat chloride values in a dose-dependent manner (p=0.0013) that was statistically significant in the 100 and 200 mg dose groups. There was no statistically significant improvement in CFTR function in the nasal epithelium as measured by nasal potential difference, nor were there statistically significant changes in lung function or patient-reported outcomes. No maturation of immature F508del-CFTR was detected in the subgroup that provided rectal biopsy specimens. Conclusions: In this study, VX-809 had a similar adverse event profile to placebo for 28 days in F508del-CFTR homozygous patients, and demonstrated biological activity with positive impact on CFTR function in the sweat gland. Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those measurable in the respiratory tract and to long-term measures of clinical benefit. Clinical trial number: NCT00865904.

Original languageEnglish
Pages (from-to)12-18
Number of pages7
Issue number1
StatePublished - Jan 2012


Dive into the research topics of 'Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation'. Together they form a unique fingerprint.

Cite this